Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3047% below fair value
$1.32−0.04 (-2.94%)
Close on Nov 16, 2026Market cap $6.07MP/E –Yield –
Biomerica operating margin
Operating margin is operating income as a percentage of revenue.
Biomerica's operating margin for the twelve months ending Aug 31, 2026 was -125.2%. For fiscal 2026 it was -119.5%, against -96.7% the year before. The highest annual figure on record is 8.3% in fiscal 2012.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | May 31, 2026 | -119.5% | −22.7 |
| FY2025 | May 31, 2025 | -96.7% | +20.9 |
| FY2024 | May 31, 2024 | -117.6% | +17.7 |
| FY2023 | May 31, 2023 | -135.3% | −111.3 |
| FY2022 | May 31, 2022 | -24.0% | +80.2 |
| FY2021 | May 31, 2021 | -104.2% | −63.2 |
| FY2020 | May 31, 2020 | -41.0% | +5.4 |
| FY2019 | May 31, 2019 | -46.4% | −19.8 |
| FY2018 | May 31, 2018 | -26.6% | −10.1 |
| FY2017 | May 31, 2017 | -16.5% | −0.4 |
| FY2016 | May 31, 2016 | -16.1% | −2.6 |
| FY2015 | May 31, 2015 | -13.5% | −4.8 |
| FY2014 | May 31, 2014 | -8.7% | −16.7 |
| FY2013 | May 31, 2013 | 7.9% | −0.4 |
| FY2012 | May 31, 2012 | 8.3% | +11.0 |
| FY2011 | May 31, 2011 | -2.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -97.0% | −16.0 |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -175.2% | +33.6 |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -131.5% | −23.4 |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -113.5% | −52.8 |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | -81.0% | −5.3 |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -208.8% | −71.9 |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -108.1% | +88.5 |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -60.7% | +41.9 |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -75.7% | −3.8 |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -136.9% | +28.8 |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -196.7% | −48.1 |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -102.6% | +9.8 |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -71.9% | +54.5 |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -165.7% | −132.6 |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -148.6% | −147.2 |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -112.4% | −88.1 |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -126.5% | −4.4 |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -33.1% | +130.3 |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -1.4% | +58.3 |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -24.3% | +100.5 |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -122.1% | +44.0 |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -163.4% | −133.1 |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -59.7% | +18.1 |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -124.8% | −94.1 |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -166.1% | −123.4 |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -30.3% | +35.3 |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -77.7% | −21.7 |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -30.7% | +1.7 |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -42.7% | −6.9 |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -65.6% | −8.6 |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -56.1% | −32.6 |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -32.4% | −14.5 |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -35.7% | −20.1 |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -57.0% | −32.7 |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -23.5% | −2.3 |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -17.9% | −2.6 |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -15.6% | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -24.2% | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -21.2% | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -15.3% | – |
See a number that looks wrong?